Aernoud Fiolet

378 Chapter 15 18. 18. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369:1522–8. 19. FioletATL, SilvisMJM, Opstal TSJ, et al. Short-termeffect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS One. 2020;15:e0237665. 20. Opstal TSJ, Hoogeveen RM, Fiolet ATL, et al. Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic CoronaryArteryDisease: ALoDoCo2 Proteomic Substudy. Circulation. 2020;142:1996–8. 21. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119–31. 22. Leung YY, Hui LLY, Kraus VB. Colchicine—Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341–50. 23. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41. 24. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720–32. 25. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61. 26. White JG. Effects of colchicine and vinca alkaloids on human platelets. 3. Influence on primary internal contraction and secondary aggregation. Am J Pathol. 1969;54:467–78. 27. Cirillo P, Taglialatela V, Pellegrino G, et al. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Thromb Thrombolysis. 2020;50:468– 72. 28. Shah B, Allen N, Harchandani B, et al. Effect of Colchicine on Platelet-Platelet and Platelet- Leukocyte Interactions: a Pilot Study in Healthy Subjects. Inflammation. 2016;39:182–9. 29. Moore GE. Cramming more components onto integrated circuits. Proc IEEE 861. 1965;86:82–5. 30. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200. 31. Munos B. Lessons from60 years of pharmaceutical innovation. Nat RevDrug Discov. 2009;8:959– 68